Kairos Pharma (NYSEAMERICAN:KAPA) Given “Buy” Rating at D. Boral Capital

Kairos Pharma (NYSEAMERICAN:KAPA)‘s stock had its “buy” rating reaffirmed by equities research analysts at D. Boral Capital in a report released on Thursday,Benzinga reports. They presently have a $9.00 price objective on the stock.

Kairos Pharma Price Performance

Shares of NYSEAMERICAN KAPA traded up $0.06 during mid-day trading on Thursday, reaching $1.00. 335,304 shares of the company traded hands, compared to its average volume of 2,693,338. Kairos Pharma has a fifty-two week low of $0.85 and a fifty-two week high of $4.00. The company has a fifty day moving average of $1.36.

About Kairos Pharma

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.